More than half patients who undergo axillary lymph node (ALN) surgery are ALN negative in early-stage invasive breast cancer (EIBC). Thus, to avoid excessive treatment, we aim to establish and validate a novel nomogram model for the preoperative diagnosis of ALN status in patients with EIBC. In total, 864 patients with EIBC from two independent centers were enrolled in our study. For the discovery set, miRNAs expression profiling with functional roles in ALN metastasis was discovered by microarray analysis and validated by quantitative polymerase chain reaction (PCR). For the training and validation cohorts, we used PCR to quantify miRNAs expression in a model development cohort and assessed miRNAs signature in an internal validation cohort and external independent validation cohort. Multivariable logistic regression analyses were used to establish a nomogram model for the likelihood of ALN metastasis from miRNAs signature and clinical variables. A signature of nine-miRNA was significantly associated with ALN status. The predictive ability of our nomogram that included miRNAs signature and clinicalrelated variables (age, tumor size, tumor location and axillary ultrasound-reported ALN status) was significantly greater than a model that only considered clinical-related factors (concordance index: 0.856, 0.796) and also performed well in the two validation cohorts (concordance index: 0.841, 0.747). Our nomogram is a reliable prediction method that can be conveniently used to preoperatively predict ALN status in patients with EIBC. Therefore, after further confirmation in prospective and multicenter clinical trial, omission of axillary surgery may be feasible for some patients with EIBC in the future.
then in these cases, any types of axillary surgery can be considered as a significant overtreatment. 6 Preoperative knowledge of ALN status can provide valuable information for determining the need for adjuvant therapy and the adequacy of surgical resection, thus aiding in pretreatment decision making. A recent study revealed that Radiomics, combined with clinical risk factors, could reach high predictive accuracy in the preoperative detection of lymph node metastasis in colorectal cancer. 7 However, the identification of metastatic disease to ALN in EIBC patients remains a challenge despite advances in imaging, molecular genetics and cancer cell biology. 6 Therefore, it is of great clinical importance to select those patients that may safely omit axillary surgery.
The term microRNA (miRNA) signatures has attracted increased attention in recent years, which could potentially be used as predictive or prognostic biomarkers. [8] [9] [10] [11] [12] [13] The combined analysis of a panel of biomarkers, rather than individual analyses, as a nomogram is the most promising approach that is powerful enough to change clinical management. 7, [14] [15] [16] Although classifier models based on clinical-associated factors, such as axillary ultrasound (AUS) and tumor size, have been investigated and demonstrated to be useful for ALN metastasis prediction in patients with BC, an optimal approach that combines multiple miRNAs biomarkers as a predictive signature has yet to be developed. [17] [18] [19] [20] To the best of our knowledge, there is no literature that has determined whether a miRNAs signature would enable superior prediction of ALN status.
As the least absolute shrinkage and selection operator (LASSO) method has been demonstrated to be a popular method for variable selection with high-dimensional data, 9, 21 we used LASSO-based methods to develop and validate a novel nomogram model that incorporated both the miRNAs signature and clinical-related risk features for the individual preoperative prediction of ALN status in patients with EIBC. We evaluated the predictive accuracy of this nomogram model in the internal and external validation groups.
Methods

Study design
Discovery cohort. Differential RNAs expression analysis by microarray was used to identify miRNAs differentially expressed in primary BC tumor tissues that have developed ALN metastases or not. To generate miRNA expression profiles, 24 fresh tumor samples were obtained from BC patients whose tumor size are <3 cm at Sun Yat-sen University Cancer center (SYSUCC) between July 1, 2011 and June 30, 2013. Additionally, 12 patients with ALN metastasis were matched with the other 12 patients who were ALN nonmetastasis according to tumor size and molecular subtypes (Supporting Information Table S1 ). We then assessed differential miRNAs expression between primary tumor tissues with or without lymph node metastasis pathologically. Details for microarray profiling and analysis can be found in Supporting Information Appendix A1.
Model development and validation cohorts. A total of 840 pathologically fresh-frozen paraffin-embedded (FFPE) BC specimens were collected for the model development and validation. Among them, 636 specimens were from SYSUCC. We randomly assigned 318 of these patients to the training cohort, and the other 318 patients to the internal validation cohort. The training and internal validation cohorts of our study comprised an evaluation of the institutional database for medical records from January 2012 to December 2014 to identify patients with pathologically confirmed BC who underwent ALN surgery with curative intent. Two pathologists (Shumei Yan and Hailin Tang) reassessed all these samples. An independent external validation cohort of 204 consecutive patients who fulfilled the same requirements as above were recruited from First Affiliated Hospital of Guangzhou Medical University (GZMUFAH) between January 2010 and August 2016. Ethical approval and written informed consent were obtained for the retrospective analysis. All data in our study have been recorded at Sun Yat-sen University Cancer Center (number RDDB2017000064). See Supporting Information Appendix A2 for more details about the inclusion and exclusion criteria of patients.
miRNAs expression by quantitative PCR
We isolated total RNA as described previously. 9 All the FFPE specimens of patients were collected during operation by surgery method and were stored at room temperature. For FFPE sections, ten 8-lm sections were cut from the FFPE blocks of biopsies after pathological examination. RNA purification was from FFPE tissue (Ambion, Life Technologies, Carlsbad, CA). qRT-PCR was done using the Platinum SYBR Green qPCR Super Mix-UDG reagents (Invitrogen, Carlsbad, CA) and Bulge-Loop primers (Generay) on the LightCycler480 system (Roche, Indianapolis, IN) with small nuclear RNA U6 as the normalization control. The qRT-PCR assay for each miRNA in each patient was repeated three times independently. Reactions without RNA template or reverse transcriptase were used as negative controls. Thirty-five candidate miRNAs were detected in the training and internal testing groups, while only nine miRNAs were measured in the independent cohort because our developed miRNAs signature just contained nine miRNAs. Forty-six samples in our study with a weak signal were excluded, and the remaining 840 cases were used for model research. We calculated the relative expression of miRNAs with the DDCT equation, in which the expression pattern in ALN negative tissue is subtracted from that identified in ALN positive tissue. The primers used in the current study are showed in Supporting Information Table S2 .
AUS assessment and evaluation criteria
All enrolled patients should undergo AUS to assess the morphology appearance of the ALNs. To standardize the evaluation of lymph nodal status before surgery, retrospective central review of archived images from the preoperative AUS was conducted by at least two ultrasound doctors, who were blinded to clinical characteristics and postoperative pathological findings. Classification of normal versus abnormal lymph node morphology was based on the cortex and hilum of the lymph node. If the cortex of a lymph node was focally or diffusely thickened (>3 mm thick) and the fatty hilum was deformed or absent, then abnormal was confirmed, while a lymph node was deemed normal if the cortex was hyperechoic and thin (3 mm thick) and the fatty hilum was visible. Their results were in complete agreement in approximately 92% of the cases. A third ultrasound doctor was consulted when a difference of opinion arose between the two primary doctors. If the third doctors agreed with one of them, then that value was selected. If the conclusion by the third doctor was completely different, then the three of them worked collaboratively to find a definite answer.
Statistical analysis
All the statistical analysis was performed with the SPSS software (version 20, SPSS Inc., Chicago, IL) and R software (version 3.2.3; http://www.Rproject.org). The packages of R used in our study are as follows: "glmnet," "rms," "Hmisc," and "Dca.R." The conventional two-sided tests, and a significance level of 0.05 were used in all analyses. We compared the two groups using Mann-Whitney U test for continuous variables and the v 2 test for categorical variables. We used the LASSO regression model to select the most useful prediction molecular markers of all the EIBC ALN metastasisassociated miRNAs identified with the training set, and constructed a miRNAs-based classifier for predicting the ALN status of patients with EIBC in the training set. The logistic regression model was performed for multivariate analysis using a backward selection procedure. The Receiver Operating Characteristic (ROC) curves were employed to test the sensitivity and specificity of variables in predicting ALN metastasis. Coefficients for each variable and the constant in the equation were generated based on multivariate analysis. A nomogram was constructed to be a graphic representation of the prediction model. The performance of the prediction model developed using the training cohort was validated by assessing the calibration curves and concordance index (Cindex). To evaluate the clinical value of our nomogram, decision curve analysis (DCA) was also conducted to estimate a net benefit for the prediction model by adding the benefits (true positives) and subtracting the harms (false positives).
22
Results
Clinical characteristics
The flow chat of the study design is showed in Figure 1 . There were 636 patients with EIBC included from SYSUCC and 204 patients from GZMUFAH. Baseline clinical and pathological characteristics of the study participants in the training and validation cohorts are listed in Table 1 . The baseline clinicopathologic factors were similar in the three cohorts. The rates of ALN metastasis were 49.1%, 42.4% and 43.5% in the training and two validation cohorts, respectively. Moreover, the patients and tumor characteristics also have no significant difference after subgroup stratification according to ALN status in the three cohorts (Supporting Information Table S3 ). However, due to ultrasound examination is partly dependent on subjective judgment, there was a temporal disconnect in the accuracy of the AUS-reported ALN status (AUS_LN) between two study centers (C-index: 0.742 for SYSUCC and 0.689 for GZMUFAH).
Development and validation of a nine-miRNA signature to distinguish ALN status of EIBC
In the discovery cohort, we ran Agilent Human miRNAs Arrays for miRNAs expression on a group of 24 EIBC and demonstrated that 35 microRNAs had the potential to separate ALN nonmetastasis EIBC from ALN metastasis EIBC (Supporting Information Figure S1A ). To avoid tumor heterogeneity, we included patients from four different molecular subtypes of BC in this cohort (Supporting Information  Table S1 ).
In the training cohort, we used LASSO logistic regression method and identified 9 miRNAs from the 35 differentially expressed miRNAs with the highest frequency of being selected by this method among 200 bootstrap replicates, which were as follow: hsa-miR-30b-5p, hsa-miR-148a-3p, hsa-miR-29c-3p, hsa-miR-29c-5p, hsa-miR-26a-5p, hsa-miR-361-3p, hsa-miR-645, hsa-miR-652-5p and hsa-miR-934. The nine miRNAs signature were significantly associated with ALN status (Figures 2a and 2b ). In the nine miRNAs, expression levels of three miRNAs (hsa-miR-645, hsa-miR-652-5p and hsa-miR-934) were positively associated with ALN metastasis, and the expression level of the other six miRNAs was inversely associated with ALN metastasis. The nine miRNAs signature were calculated and presented in the Supporting Information Appendix A3. Distributions of the miRNAs signature and ALN status in training and validation cohorts are also given in the Supporting Information Table S3 . The nine-miRNA signature had an C-index 0.745 (95% CI 0.690-0.799) to discriminate individuals with ALN nonmetastasis from all patients with EIBC in training cohort, 0.721 (95% CI, 0.663-0.779) and 0.714 (95% CI, 0.640-0.788) in the internal and external validation cohorts, respectively, while the C-index for AUS_LN is 0.72 in the SYSUCC and 0.689 in the GZMUFAH (Figures 2c-2e) . Moreover, C-index for miRNAs signature were 0.792 (0.715-0.870), 0.695 (0.603-0.787) and 0.739 (0.684-0.793) for detection of AUS-reported ALN negative EIBC in the training cohort, internal and external validation cohorts, respectively. Stratified by molecular subtypes, miRNAs signature still hold well, especially in triple negative BC (Figures 2f-2h ). Pathway analysis for nine miRNAs in the model is showed in Supporting Information Figure S1B .
Nomogram combined miRNAs signature and clinical-related factors predicts ALN status
A cohort of 318 patients, of whom 130 (40.9%) had nodal metastasis on ALN surgery, was used to first develop a model of the likelihood of ALN metastasis based on clinical-related factors of the primary tumor (Table 2 and Supporting Information Table S3 ). In the training cohort, each significant variable was evaluated by univariate logistic regression analysis for assessing the independent risk factors of presence of ALN metastasis (Supporting Information Table S4 and Figure S2 ). Multivariable logistic regression modeling found age, tumor size, tumor location and AUS_LN were associated with an increased likelihood of ALN metastasis detected by ALND (Table 2 and Supporting Information Table S4 , clinicalrelated nomogram model). Then we assessed the additional contributions made by the above constructed nine-miRNA signature. Finally, a logistic regression analysis was used to develop a nomogram model that combined the clinicalrelated factors (age, tumor size, tumor location and AUS_LN) and miRNAs signature ( Figure 3a ; Table 2 and Supporting Information Table S4 ). The overall discriminatory ability of the clinical-related nomogram model (C-index, 0.796; 95% CI, 0.746-0.847; Supporting Information Figure S2E ) was significantly improved with the addition of the miRNAs signature (C-index for miRNAs nomogram model, 0.856; 95% CI, 0.815-0.897; p < 0.001; Figure 3e and Supporting Information Table S5 ). The calibration curve also showed good calibration by miRNAs nomogram in the training set ( Figure 3b ). Having developed a novel and promising nomogram model to predict the likelihood of ALN metastasis of EIBC, we then examined its predictive ability in our validation cohorts ( Figure 3 and Supporting Information Figure S2 ). In agreement with the above results, the favorable calibration of the miRNAs nomogram was confirmed with the validation cohorts (Figures 3c and 3d ; Supporting Information Figures  S2C and S2D ). In the two validation cohorts, the miRNAs nomogram displayed a C-index of 0.841 (95% CI, 0.795-0.887) and 0.747 (95% CI, 0.677-0.817) for the estimation of ALN metastasis risk, respectively (Figures 3f and 3g ; Supporting Information Table S5 ; Supporting Information Figure S3 and Figure S4 ). In addition, when miRNAs nomogram was used in differentiating the presence from absence of ALN metastasis, the sensitivity, specificity, positive predictive value, and negative predictive value were 87.7%, 72.3%, 68.7% and 89.5% in the training cohort, and 79.1%, 72.8%, 67.9% and 82.7% in the internal validation cohort, and 81.0%, 71.2%, 64.0% and 85.6% in the external validation cohort, respectively (Supporting Information Table S6 ). Moreover, miRNAs nomogram showed a high net benefit to inform clinical decisions for a risk probability thresholds between 0% and 80% in common clinical practice according to DCA (Figure 4) . These results also indicate that miRNAs nomogram improves current treatment standards. 
Discussion
An effective molecular-based method to identify patients with EIBC who have ALN metastasis is urgently needed to optimize the tailored therapy in the era of precision medicine. In our study, we used miRNAs microarray to screen differential miRNAs in a discovery cohort and selected 35 significant miRNAs according to the likelihood of patients with ALN metastasis. Next, in the training cohort, based LASSO method, we selected nine candidate miRNAs and constructed a miRNAs signature. Moreover, we validated the miRNAs signature in the internal and external validation cohorts. With this miRNAs signature, patients with ALN metastasis may be detected before axillary surgery. Moreover, in AUSreported ALN negative EIBC patients, the developed miRNA signature hold robust function as well. Furthermore, we established a miRNAs nomogram including miRNAs signature and clinical-related risk factors (age, tumor size, tumor location and AUS-reported ALN status) to predict ALN status before axillary surgery. The performance of our nomogram was also verified in the two validation cohorts. The subgroup of patients with a very low risk of ALN metastasis identified with the nomogram tool might be candidate for observation strategy and no axillary surgery is indeed required. On the other hand, for the patients with high risk of ALN metastasis, ALND should be conducted directly and SLNB is no longer necessary. Thus, our nomogram may help guide preoperative prediction of ALN status and make individualized therapeutic decision for patients with EIBC. Multiple gene expression-based testing, such as the 21-Gene Recurrence Score Assay and 70-Gene Signature, has been successfully used to provide predictive or prognostic information for BC patients and guide individualize therapy. 23, 24 Previous research on miRNA expression profiling consistently demonstrated that miRNA-based signature is a potential predictor for progression or relapse in patients with epithelial ovarian cancer. 25 Also, our previous study found BC stem cells expressing a unique profile of miRNAs and then a 10-miRNA-based classifier was constructed, which was demonstrated to be a reliable prognostic and predictive model for disease recurrence, and may help to predict benefit of adjuvant chemotherapy in some BC patients. 9 Recently, several studies are evaluating the patient's likelihood of ALN metastasis in BC, including estimated risks of SLN metastasis or non-SLN metastasis. Dihge et al. 26 presented a noninvasive predictive nomogram model, with an C-index of 0.74 for N0 versus any lymph node metastasis. The above predictive model includes clinicopathological factors such as tumor size, vascular invasion and molecular subtype, and so on but lacks AUS and molecular markers detection. Ongoing prospective randomized studies will examine the role of AUS and may answer the question of whether SLNB may be omitted in some early low-risk BC patients. 27 However, the evaluation results of AUS may vary between examiners, and the overall accuracy of AUS remains controversial, especially in low-burden lymph node disease. A miRNA-based prediction model for lymph node metastasis in hepatocellular carcinoma has been developed, which can effectively and accurately classify patients into groups with low risk or high risk of developing lymph node metastasis. 28 Our study here first evaluated the usefulness of miRNAs signature as an effective molecular approach for the preoperative diagnosis of ALN metastases in EIBC. The results suggest that the evaluation of nine miRNAs expression could be an important tool for the management of EIBC patients, Figure 4 . Decision curve analysis of the prediction nomogram model in (a) training cohort, (b) internal validation cohort and (c) external validation cohort. The y axis displays the net benefit, which was calculated by minusing the proportion of false-positive patients from the proportion of true positive patients, weighting by the relative harm of giving up treatment compared to the negative effects by unnecessary treatment. Solid black line: net benefit when all breast cancer patients are considered as not having the ALN metastasis; solid gray line: net benefit when all breast cancer patients are considered as having the event. Dashed black line: net benefit when all breast cancer patients are considered according to the developed miRNAs nomogram model. In our current study, the decision curves in both the training and validation cohorts showed that if the threshold probability is between 0 and 0.80, then using the miRNAs nomogram to predict ALN metastases adds more benefit than treating either all or no patients, while the ideal model is the model with the highest net benefit at any given threshold. assisting in the stratification of patients that may harbor ALN metastases, aiding in therapy planning and patient staging, ultimately contributing to an improvement in quality of life and survival rates.
We determined a set of nine miRNAs that define ALN metastasis in EIBC. Most of the miRNAs found to be dysregulated in primary tumor tissues from patients with EIBC have been investigated to be involved in the cell invasion and prognosis of cancer. The miR-29c, miR-148a and miR-361 have been found to be related to cell growth, invasion and epithelial-to-mesenchymal transition in many cancers and are involved in many oncogene signaling.
11,29-32 miR-26a and miR-30b might play an vital role in acquired trastuzumab resistance in HER2 positive BC. 33, 34 These above tumor suppressor miRNAs were all negatively correlated with ALN metastasis. On the other hand, miR-645 targets the interferon-induced protein with tetratricopeptide repeats 2, a mediator of apoptosis via a mitochondrial pathway, resulting in increased cancer cell motility and adhesion. 35 Upregulation of miR-652 is often found in many types of cancer and may promote cell proliferation and metastasis. [36] [37] [38] These tumor promoter miRNAs were positively correlated with ALN metastasis. Functional enrichment analysis of KEGG signaling pathway has showed the top 20 pathway involved, such as PI3K-Akt signaling pathway and so on.
However, there are still several limitations in our current study as well. First, it is retrospective and inherent biases and variations of such a study format could have influenced results. Second, the tumor samples used to detect miRNAs expression are derived from tumor excision biopsy tissues, not from tumor coarse needle puncture tissues. As most of patients with EIBC are diagnosed by routine preoperative coarse needle puncture, which can provide minimally invasive diagnosis of tumors and guide treatment decisions, then to disseminate and apply our research results in current clinical practice merits further investigation. Third, model establishment and validation cohorts were all from the same ethnic group patients seeking care in hospitals of China. As BC patients in China are often younger than in other contries, our prediction model cannot be directly applied in nonAsia patients. Fourth, although miRNAs nomogram showed good predictive accuracy, it had 27.7% and 12.3% falsepositive and false-negative rates in the training cohort, 27.2% and 20.9% in the internal validation cohort and 28.8% and 19.0% in the external validation cohort, respectively, for predicting ALN metastasis, which remains high for major clinical treatment decisions. Therefore, our results should be further confirmed and incorporated with other specific markers in prospective, large-scale, multiethnic and multicenter clinical trials.
Conclusions
To our knowledge, our study possesses the largest multimolecular markers analysis of primary tumor of EIBC with known ALN status to date and reveals an association between miRNAs expression and ALN status. Our results suggest that the miRNAs signature obtained by gene expressing profiling can be combined with age, tumor size, tumor location and AUS-reported ALN status to precisely calculate the predicted probability of ALN status prior to operation. This novel nomogram model has the potential and can be conveniently used to optimize current treatment strategy by avoiding unnecessary ALN procedures in EIBC.
